Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways

Journal of Immunology

Volumn 180, Issue 7, 2008, Pages 4687-4696

  Das, Tanya ^c   Sa, Gaurisankar ^c   Paszkiewicz Kozik, Ewa ^a,d   Hilston, Cynthia ^a   Molto, Luis ^a   Rayman, Patricia ^a   Kudo, Daisuke ^a   Biswas, Kaushik ^a   Bukowski, Ronald M ^b   Finke, James H ^a   Tannenbaum, Charles S ^a,e  

^a Department of Immunology   (India)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c BOSE INSTITUTE   (India)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GANGLIOSIDE; DEATH RECEPTOR; FADD PROTEIN, HUMAN; FAS ANTIGEN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LEUKEMIA CELL LINE; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; T LYMPHOCYTE; WESTERN BLOTTING; CELL CULTURE; COCULTURE; CYTOLOGY; ENZYME ACTIVATION; GENETICS; METABOLISM; MITOCHONDRION; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, RENAL CELL; CASPASE 8; CASPASE 9; CELLS, CULTURED; COCULTURE TECHNIQUES; ENZYME ACTIVATION; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GANGLIOSIDES; HUMANS; MITOCHONDRIA; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 44449160500     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.7.4687     Document Type: Article

References (52)

1. Nielsen, M. B., and F. M. Marincola. 2001. Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother. Pharmacol. 46(Suppl.): S62-S66.
2. Finke, J., S. Ferrone, A. Frey, A. Mufson, and A. Ochoa. 1999. Where have all the T cells gone: mechanisms of immune evasion by tumors. Immunol. Today 20: 158-160.
3. Maggard, M., L. Meng, B. Ke, R. Allen, L. Devgan, and D. K. Imagawa. 2001. Antisense TGF-β2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Ann. Surg. Oncol. 8: 32-37.
4. Real, L. M., P. Jimenez, A. Kirkin, A. Serrano, A. Garcia, J. Canton, J. Zeuthen, F. Garrido, and F. Ruiz-Cabello. 2001. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol. Immunother. 49: 621-628.
5. Elnemr, A., T. Ohta, A. Yachie, M. Kayahara, H. Kitagawa, I. Ninomiya, S. Fushida, T. Fujimura, G. Nishimura, K. Shimizu, and K. Miwa. 2001. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Int. J. Oncol. 18: 33-39.
6. Salazar-Onfray, F. 1999. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med. Oncol. 16: 86-94.
7. Uzzo, R. G., P. Rayman, V. Kolenko, P. E. Clark, T. Bloom, A. M. Ward, L. Molto, C. Tannenbaum, L. J. Worford, R. Bukowski, et al. 1999. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. 5: 1219-1229.
8. Rabinowich, H., T. E. Reichert, Y. Kashii, B. R. Gastman, M. C. Bell, and T. L. Whiteside. 1998. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101: 2579-2588.
9. + T lymphocytes in peripheral blood of patients with advanced melanoma. Clin. Cancer Res. 6: 1351-1364.
10. Gastman, B. R., D. E. Johnson, T. L. Whiteside, and H. Rabinowich. 2000. Tumor-induced apoptosis ofTlymphocytes: elucidation of intracellular apoptotic events. Blood 95: 2015-2023.
11. Gastman, B. R., Y. Atarshi, T. E. Reichert, T. Saito, L. Balkir, H. Rabinowich, and T. L. Whiteside. 1999. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59: 5356-5364.
12. Whiteside, T. L., and H. Rabinowich. 1998. The role of Fas/FasL in immuno-suppression induced by human tumors. Cancer Immunol. Immunother. 46: 175-184.
13. Kozlowski, M., O. Kowalczuk, A. Sulewska, P. Dziegielewski, G. Lapuc, W. Laudanski, W. Niklinska, L. Chyczewski, J. Niklinski, and J. Laudanski. 2007. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus. Folia Histochem. Cytobiol. 45: 199-204.
14. Baldini, E., S. Ulisse, E. Marchioni, A. Di Benedetto, G. Giovannetti, E. Petrangeli, S. Sentinelli, R. P. Donnorso, M. G. Reale, M. Mottolese, et al. 2007. Expression of Fas and Fas ligand in human testicular germ cell tumours. Int. J. Androl. 30: 1-8.
15. Uzzo, R. G., P. Rayman, A. C. Novick, R. M. Bukowski, and J. H. Finke. 2000. Molecular mechanisms of immune dysfunction in renal cell carcinoma. In Renal Cell Carcinoma: Molecular Biology, Immunology and Clinical Management. R. M. Bukowski and A. C. Novick, eds. Humana Press, Totowa, pp. 63-78.
16. Zaks, T. Z., D. B. Chappell, S. A. Rosenberg, and N. P. Restifo. 1999. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162: 3273-3279.
17. Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448.
18. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184: 1075-1082.
19. Greil, R., A. Egle, and A. Villunger. 1998. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Leuk. Lymphoma 31: 477-490.
20. Kume, T., K. Oshima, Y. Yamashita, T. Shirakusa, and M. Kikuchi. 1999. Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach. Int. J. Cancer 84: 339-343.
21. Saas, P., P. R. Walker, M. Hahne, A. L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E. G. Van Meir, N. de Tribolet, J. Tschopp, and P. Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99: 1173-1178.
22. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1999. Fas counter-attack-the best form of tumor defense? Nat. Med. 5: 267-228.
23. Nagata, S. 1996. Fas ligand and immune evasion. Nat. Med. 2: 1306-1137.
24. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1997. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol. Med. 3: 294-300.
25. Inman, B. A., T. J. Sebo, X. Frigola, H. Dong, E. J. Bergstralh, I. Frank, Y. Fradet, L. Lacombe, and E. D. Kwon. 2007. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109: 1499-1505.
26. Morales, J. C., M. J. Ruiz-Magana, and C. Ruiz-Ruiz. 2007. Regulation of the resistance to TRAIL-induced apoptosis in human primary Tlymphocytes: role of NF-κB inhibition. Mol. Immunol. 44: 2587-2597.
27. Bennett, M. W., J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. K. Collins, and F. Shanahan. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160: 5669-5575.
28. Uzzo, R. G., P. Rayman, V. Kolenko, P. E. Clark, M. K. Cathcart, T. Bloom, A. C. Novick, R. M. Bukowski, T. Hamilton, and J. H. Finke. 1999. Renal cell carcinoma-derived gangliosides suppress nuclear factor-κB activation in T cells. J. Clin. Invest. 104: 769-776.
29. Raval, G., S. Biswas, P. Rayman, K. Biswas, G. Sa, S. Ghosh, M. Thornton, C. Hilston, T. Das, R. Bukowski, et al. 2007. TNF-α induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction. J. Immunol. 178: 6642-6652.
30. Kudo, D., P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke. 2003. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells Cancer Res. 63: 1676-1683.
31. Hengartner, M. O. 2001. The biochemistry of apoptosis. Nature 407: 770-776.
32. Schmitz, I., H. Walczak, P. H. Krammer, and M. E. Peter. 1999. Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ. 6: 821-822.
33. Juo, P., C. J. Kuo, J. Yuan, and J. Blenis. 1998. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 8: 1001-1008.
34. Chinnaiyan, A. M., K. O'Rourke, M. Tewari, and V. M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
35. Ebert, T., N. H. Bander, C. L. Finstad, R. D. Ramsawak, and L. J. Old. 1990. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 50: 5531-5556.
36. Jodo, S., D. Strehlow, and S. T. Ju. 2001. Bioactivities of Fas ligand-expressing retroviral particles. J. Immunol. 164: 5062-5069.
37. Jodo, S., S. Xiao, A. Hohlbaum, D. Strehlow, A. Marshak-Rothstein, and S. T. Ju. 2001. Apoptosis-inducing membrane vesicles: a novel agent with unique properties. J. Biol. Chem. 276: 39938-39944.
38. Thornton, M. V., D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al. 2004. Degradation of NF-κB in T cells by gangliosides expressed on renal cell carcinomas. J. Immunol. 172: 3480-3490.
39. Darzynkiewicz, Z., S. Bruno, G. Del Bino, W. Gorczyca, M. A. Hotz, P. Lassota, and F. Traganos. 1992. Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808.
40. Kolenko, V., T. Bloom, P. Rayman, R. Bukowski, E. Hsi, and J. Finke. 1999. Inhibition of NF-κB activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and-3. J. Immunol. 163: 590-598.
41. Zamzami, N., P. Marchetti, M. Castedo, C. Zanin, J. L. Vayssiere, P. X. Petit, and G. Kroemer. 1995. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181: 1661-1672.
42. Bratton, D. L., V. A. Fadok, D. A. Richter, J. M. Kailey, S. C. Frasch, T. Nakamura, and P. M. Henson. 1999. Polyamine regulation of plasma membrane phospholipid flip-flop during apoptosis. J. Biol. Chem. 274: 28113-28120.
43. Biswas, K., A. Richmond, P. Rayman, S. Biswas, M. Thornton, G. Sa, T. Das, R. Zhang, A. Chahlavi, C. S. Tannenbaum, et al. 2006. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res. 66: 6816-6825.
44. Juo, P., M. S. Woo, C. J. Kuo, P. Signorelli, H. P. Biemann, Y. A. Hannun, and J. Blenis. 1999. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 10: 797-804.
45. Perkins, C. L., G. Fang, C. N. Kim, and K. N. Bhalla. 2001. The role of Apaf-1, caspase-9, and bid proteins in etoposide-or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 60: 1645-1153.
46. Gastman, B. R., X. M. Yin, D. E. Johnson, E. Wieckowski, G. Q. Wang, S. C. Watkins, and H. Rabinowich. 2001. Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade. Cancer Res. 60: 6811-6687.
47. Nagata, S. 1997. Apoptosis by death factor. Cell 88: 355-365.
48. Krammer, P. H. 2001. CD95's deadly mission in the immune system. Nature 407: 789-795.
49. Liu, X., C. N. Kim, J. Yang, R. Jemmerson, and X. Wang. 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147-157.
50. Zou, H., W. J. Henzel, X. Liu, A. Lutschg, and X. Wang. 1997. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413.
51. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M. Debatin, P. H. Krammer, and M. E. Peter. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675-1187.
52. Fas, S. C., S. Baumann, A. Krueger, C. R. Frey, H. Schulze-Bergkamen, D. Brenner, C. Stumpf, K. Kappes, and P. H. Krammer. 2006. In vitro generated human memory-like T cells are CD95 type II cells and resistant towards CD95-mediated apoptosis. Eur. J. Immunol. 36: 2894-2903.